Post a Free Blog

Submit A Press Release

Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Action
Animation
ATP Tour (ATP)
Auto Racing
Baseball
Basketball
Boxing
Breaking News
Business
Business
Business Newsletter
Call of Duty (CALLOFDUTY)
Canadian Football League (CFL)
Car
Celebrity
Champions Tour (CHAMP)
Comedy
CONCACAF
Counter Strike Global Offensive (CSGO)
Crime
Dark Comedy
Defense of the Ancients (DOTA)
Documentary and Foreign
Drama
eSports
European Tour (EPGA)
Fashion
FIFA
FIFA Women’s World Cup (WWC)
FIFA World Cup (FIFA)
Fighting
Football
Formula 1 (F1)
Fortnite
Golf
Health
Hockey
Horror
IndyCar Series (INDY)
International Friendly (FRIENDLY)
Kids & Family
League of Legends (LOL)
LPGA
Madden
Major League Baseball (MLB)
Mixed Martial Arts (MMA)
MLS
Movie and Music
Movie Trailers
Music
Mystery
NASCAR Cup Series (NAS)
National Basketball Association (NBA)
National Football League (NFL)
National Hockey League (NHL)
National Women's Soccer (NWSL)
NBA Development League (NBAGL)
NBA2K
NCAA Baseball (NCAABBL)
NCAA Basketball (NCAAB)
NCAA Football (NCAAF)
NCAA Hockey (NCAAH)
Olympic Mens (OLYHKYM)
Other
Other Sports
Overwatch
PGA
Politics
Premier League (PREM)
Romance
Sci-Fi
Science
Soccer
Sports
Sports
Technology
Tennis
Thriller
Truck Series (TRUCK)
True Crime
Ultimate Fighting Championship (UFC)
Uncategorized
US
Valorant
Western
Women’s National Basketball Association (WNBA)
Women’s NCAA Basketball (WNCAAB)
World
World Cup Qualifier (WORLDCUP)
WTA Tour (WTA)
Xfinity (XFT)
XFL
0
-- Advertisement --spot_img
HomeBusinessMerck asks FDA for EUA for COVID-19 pill that halves hospitalizations and...

Merck asks FDA for EUA for COVID-19 pill that halves hospitalizations and death

Add to Favorite
Added to Favorite



On Monday, Merck and partner Ridgeback Biotherapeutics LP asked the Food and Drug Administration (FDA) to give its COVID-19 pill emergency use authorization (EUA). They filed an application for their pill molnupiravir as the next step forward after receiving promising results in trials from a late-stage study. According to the company, its antiviral drug decreased hospitalizations or death due to COVID-19 by 50 percent in high risk individuals who had mild or moderate infections, as per data obtained in phase three clinical trials.

If the FDA authorizes emergency use approval, molnupiravir could become the first oral pill to be used to treat COVID-19. It reportedly stops the virus from replicating itself and this could stop its spread throughout the human body. It was originally formulated to treat influenza. It can be taken at home and would not require patients to go to hospitals to get treated.

Emory University had developed the drug at Drug Innovation Ventures at Emory (DRIVE). The drug innovation company, based in Atlanta, had licensed its use to Ridgeback Biotherapeutics, who in turn partnered with the Summit, New Jersey giant pharmaceutical Merck.

Merck has released the results of the clinical trials. The results have not been peer reviewed. Side effects were mild but were not mentioned by Merck.

According to the Daily Mail, trials were also conducted with generic versions in India but were stopped for moderate cases as the medication did not show “significant efficacy.” However, the pills were successful when used for mild cases. Incidentally different countries classify mild and moderate cases according to their own regulations.

Merck also said that it was working with other regulatory agencies around the world. It has said that the U.S. will be supplied with roughly 1.7 million courses, if the FDA authorizes EUA or full approval. The New York Times reported that a five-day course of molnupiravir would cost approximately $700 per person. Monoclonal antibodies, the current treatment, costs the federal government three times as much as that of molnupiravir.

Subscribe to get Latest News Updates

Latest News

You may like more
more

Canaccord Genuity Raises DigitalOcean Price Target to $48, Stock Soars 8 percent

Canaccord Genuity analysts increased their price target on DigitalOcean...

JPMorgan Lowers Duckhorn Portfolio Price Target to $7 Ahead of Q4 Earnings Release

JPMorgan analysts reduced their price target for The Duckhorn...

Stephens Reiterates Overweight Rating on Carvana, Highlights Market Share Growth Potential

Stephens analysts reaffirmed their Overweight rating and $190 price...